You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

Details for New Drug Application (NDA): 209606


✉ Email this page to a colleague

« Back to Dashboard


NDA 209606 describes IDHIFA, which is a drug marketed by Bristol Myers Squibb and is included in one NDA. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the IDHIFA profile page.

The generic ingredient in IDHIFA is enasidenib mesylate. One supplier is listed for this compound. Additional details are available on the enasidenib mesylate profile page.
Summary for 209606
Tradename:IDHIFA
Applicant:Bristol Myers Squibb
Ingredient:enasidenib mesylate
Patents:6
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 209606
Generic Entry Date for 209606*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 209606
Suppliers and Packaging for NDA: 209606
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
IDHIFA enasidenib mesylate TABLET;ORAL 209606 NDA Celgene Corporation 59572-705 59572-705-30 30 TABLET, FILM COATED in 1 BOTTLE (59572-705-30)
IDHIFA enasidenib mesylate TABLET;ORAL 209606 NDA Celgene Corporation 59572-710 59572-710-30 30 TABLET, FILM COATED in 1 BOTTLE (59572-710-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 50MG BASE
Approval Date:Aug 1, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 1, 2024
Regulatory Exclusivity Use:TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
Patent:⤷  Sign UpPatent Expiration:Aug 1, 2034Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
Patent:⤷  Sign UpPatent Expiration:Jan 7, 2033Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.